Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

First-of-its-Kind SOBA-AD, Blood Test Developed to Detect Alzheimer’s Disease

AltPep Corporation developed first-of-its-kind SOBA-AD assay, a simple blood test for the detection of Alzheimer’s Disease.

SOBA-AD assay is a blood test conducted to detect toxic oligomers which triggers rapid events associated with AD, such as cognitive impairment and neurodegeneration. Moreover, the SOBA-AD assay has the ability to recognise the disease early, even before symptoms arise. Early detection of AD may lead to more effective treatments that limit cognitive decline in patients.

Current FDA-cleared diagnostic tests for Alzheimer’s Disease (AD) repeat amyloid-beta plaques and neurofibrillary tangles in the brains of patients whereas SOBA-AD test detects the early molecular triggers of the disease, before plaque formation.

Alzheimer’s disease is the most widely spread form of demantia affecting currently 6 million Americans and expected to grow to 13 million in the future.

U.S. Food and Drug Administration (FDA) grants Breakthrough Device designation for its SOBA-AD diagnostic test for Alzheimer’s disease (AD).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024